This document discusses prescription drug costs and spending in the United States. It notes that while 56 new medicines were approved by the FDA in 2019, out-of-pocket costs for patients continue to rise. While overall spending on prescription drugs grew by just 2.5% in 2018, nearly half of brand drug spending goes to entities other than the manufacturers. The document also compares US drug costs and availability to other countries.